Nav: Home

Elicio Therapeutics' Darrell Irvine co-authors research published in Science

July 11, 2019

  • Research conducted at the Irvine Lab at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology is being utilized in Elicio's AMP-CAR-T Platform

  • Activation of CAR-T cells with Amphiphiles delivered to the lymph nodes induces massive CAR-T expansion, substantially improved efficacy across cancer types, and durable cures for solid tumors
CAMBRIDGE MA., July 12, 2019 - Elicio Therapeutics, a next generation immuno-oncology company, engineering therapies for cancer killing immune responses, today announced that studies of its Amphiphile platform in combination with CAR-T therapy (AMP-CAR-T) have shown that activation of CAR-T cells in the lymphatic system gives massive CAR-T cell expansion, and significant functional improvements including enhanced CAR-T cell infiltration of solid tumors, increased anti-tumor cytolytic potential, and improved cytokine response. The research, conducted in the labs of Elicio co-founder, Darrell Irvine, at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology, was published on July 12 by the journal Science, in a paper entitled "Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor."1

Through precise targeting and delivery directly to the lymphatic system, Elicio is engineering potent Amphiphile immunotherapies including cell therapy activators, immunomodulators, and vaccines for an array of aggressive cancers. The Amphiphile approach is based on the ground-breaking work of Darrell Irvine, PhD., Professor of Biological Engineering and Materials Sciences and Howard Hughes Investigator at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. The company is currently utilizing the study findings in its AMP-CAR-T platform to develop therapeutic interventions that activate and amplify CAR-T therapy to combat an array of cancers including solid tumors. In addition to enhancing the magnitude and functionality of co-administered CAR-T cells, the published data further shows that the combination of CAR-T with AMP-CAR-T activators leads to the potent induction of natural immune responses thought to be critical for improving activity in solid tumors, enabling prolonged survival and durable cures where CAR-T alone has no effect. Elicio is developing the AMP-CAR-T platform for combination with CAR-T cell therapies in a variety of settings including those targeting CD19, BCMA, and several solid tumor indications.

"CAR-Ts show great promise but historically they've had issues with durability of response and efficacy beyond hematologic cancers, which we hypothesized could be due to the lack of a means to properly stimulate these cells in vivo," said Darrell Irvine, Elicio co-founder, senior scientific advisor, and a supporting author. "What we saw in this study is that by activating CAR-T cells through their chimeric receptor in the native micro-environment of lymph nodes, it's possible to enhance CAR-T treatment of solid tumors across cancer types."

"We believe that Elicio's AMP-CAR-T platform has the potential to solve many of the major obstacles CAR-T therapy is facing by activating CAR-T cells in the lymph nodes to amplify immune responses which could lead to durable cures for aggressive, liquid and solid tumors," said Julian Adams, Ph.D., board chair, Elicio. "Elicio is developing a pipeline of AMP-CAR-T activators which when administered with CAR-T cells, or other CAR-engineered immune cells, will amplify their function for patients, creating a more powerful and lasting immune response."
About the AMP-CAR-T platform

The Elicio Amphiphile platform enables precise targeting and delivery of immunogens directly to the lymphatic system, the "brain center" of the immune response, to significantly amplify and enhance the body's own system of defenses to defeat cancer, and stop its recurrence. When combined with CAR-T therapy, AMP-CAR-T activators specifically designed to bind to the CAR receptor are presented on the cell surface of immune cells in the lymph nodes. CAR-T cells passing through the lymph nodes en route to the tumor see these AMP-CAR-T activators on the surface of specialized antigen presenting cells (APCs), which then deliver potent activating signals to T cells to coordinate their expansion, development of anti-tumor functions, and mobilization against tumors. This strategy is highly flexible for universal application with any CAR-T therapy without the need for re-engineering of the CAR-T cell design.

About Elicio Therapeutics

Elicio, based in Cambridge MA, is committed to transforming the lives of patients and their families by re-engineering the body's immune response to defeat cancer. By combining expertise in materials science and immunology, Elicio is engineering potent Amphiphile immunotherapies including lymph node targeted cell therapy activators, immunomodulators, and vaccines for an array of aggressive cancers. Elicio's lead Amphiphile vaccine targeting KRAS-driven cancers will begin initial patient studies in pancreatic and colorectal cancer patients in the first half of 2020. These programs are followed by a broad preclinical pipeline of lymph node targeted immunotherapies. For more information please visit

[1] Leyuan Ma et al. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science 2019;

Media Contact:

Liza Sullivan
Mobile: 917-981-7494


Related Lymph Nodes Articles:

Unveiling how lymph nodes regulate immune response
The Hippo pathway keeps lymph nodes' development healthy. If impaired, lymph nodes become full of fat cells or fibrosis develops.
Sentinel lymph node biopsy has no benefits for stage zero breast cancer
Older women with a very early, non-invasive breast cancer known as ductal carcinoma in situ (DCIS) gain no long-term benefit from undergoing a sentinel lymph node biopsy to see if the cancer has spread, new research by the Yale School of Public Health has found.
S1P molecule regulates dendritic cell localization and vascular integrity in lymph nodes
Researchers found that HEVs, which were deficient for the S1P-transporter Spinster-homologue-2, were unable to attract dendritic cells in order to trigger LTβr-signaling through cell-cell contact with HEVs.
Fewer lymph node operations for breast cancer patients with new prediction models
In recently published studies, researchers at Lund University and Skåne University Hospital in Sweden have produced new prediction models for improved personalised treatment of lymph nodes in breast cancer patients.
Nanoparticle therapy targets lymph node metastases
Metastasis, in which cancer cells break free from the primary tumor and form tumors at other sites, worsens the prognosis for many cancer patients.
Lymph nodes can predict survival in patients with esophageal cancer
It is difficult for physicians to estimate recurrence and survival in patients with esophageal cancer.
A peek into lymph nodes
The vast majority of cancer deaths occur due to the spread of cancer from one organ to another, which can happen either through the blood or the lymphatic system.
Lymph nodes are niches for prolonged tuberculosis infection
Lymph nodes can contain large numbers of tuberculosis-causing bacteria and serve as long-term reservoirs of bacterial persistence, according to a study published Nov.
Lymph node structural cells rein in human immune responses
New research published in PLOS Biology by Anne Fletcher and Konstantin Knoblich and colleagues, from Monash Biomedicine Discovery Institute (BDI), has veered away from traditional immunology by turning the spotlight on the structural cells that build and support the immune-rich environment of lymph nodes.
Newly identified structure in lymph nodes was 'hiding in plain sight'
For the first time in decades, researchers have identified a new 'micro-organ' within the immune system -- and they say it's an important step towards understanding how to make better vaccines.
More Lymph Nodes News and Lymph Nodes Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Meditations on Loneliness
Original broadcast date: April 24, 2020. We're a social species now living in isolation. But loneliness was a problem well before this era of social distancing. This hour, TED speakers explore how we can live and make peace with loneliness. Guests on the show include author and illustrator Jonny Sun, psychologist Susan Pinker, architect Grace Kim, and writer Suleika Jaouad.
Now Playing: Science for the People

#565 The Great Wide Indoors
We're all spending a bit more time indoors this summer than we probably figured. But did you ever stop to think about why the places we live and work as designed the way they are? And how they could be designed better? We're talking with Emily Anthes about her new book "The Great Indoors: The Surprising Science of how Buildings Shape our Behavior, Health and Happiness".
Now Playing: Radiolab

The Third. A TED Talk.
Jad gives a TED talk about his life as a journalist and how Radiolab has evolved over the years. Here's how TED described it:How do you end a story? Host of Radiolab Jad Abumrad tells how his search for an answer led him home to the mountains of Tennessee, where he met an unexpected teacher: Dolly Parton.Jad Nicholas Abumrad is a Lebanese-American radio host, composer and producer. He is the founder of the syndicated public radio program Radiolab, which is broadcast on over 600 radio stations nationwide and is downloaded more than 120 million times a year as a podcast. He also created More Perfect, a podcast that tells the stories behind the Supreme Court's most famous decisions. And most recently, Dolly Parton's America, a nine-episode podcast exploring the life and times of the iconic country music star. Abumrad has received three Peabody Awards and was named a MacArthur Fellow in 2011.